Trial Profile
Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapies; An Observational Prospective Study
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 14 Mar 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Durvalumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Trastuzumab (Primary)
- Indications Infusion related reaction
- Focus Adverse reactions
- Acronyms MINUTE
- 05 Mar 2024 Status changed from not yet recruiting to recruiting.
- 13 Sep 2023 New trial record